Erasca aims to erase cancer with precision therapies that shut down RAS/MAPK signaling; lead pan-RAS molecular glue ERAS-0015 has FDA Fast Track designation.
Products & media
An oral pan-RAS molecular glue in Phase 1 development for RAS-mutant solid tumors, including pancreatic, lung, and colorectal cancers.
An oral pan-KRAS inhibitor in the BOREALIS-1 Phase 1 trial for patients with KRAS-mutant solid tumors.
A discovery-stage EGFR D2/D3 biparatopic antibody program for EGFR-driven and RAS/MAPK-driven solid tumors that Erasca is evaluating for strategic alternatives.
Team
Current Affiliates
1 person
Jobs
See all jobs for Erasca here.
Company history
All fundraising announcements are based on public sources. Please contact Cosign if you believe there are any discrepancies, or claim the profile to edit.
Leads
Participating Firms
Angels
IPO completed · NASDAQ:ERAS